Table 1.
Baseline patient demographics and characteristics (intent-to-treat population).
| Characteristic | Median Age <44 y | Median Age ≥44 y | ||
|---|---|---|---|---|
| KarXT (n = 43) | Placebo (n = 46) | KarXT (n = 46) | Placebo (n = 44) | |
| Age, years | ||||
| Mean ± SD | 34.3 ± 5.3 | 33.4 ± 6.1 | 52.1 (4.4) | 50.7 (3.8) |
| Median (range) | 34.0 (19‒42) | 34.0 (20‒42) | 52.5 (44‒60) | 51.0 (44‒59) |
| Male sex, n (%) | 37 (86.0) | 39 (84.8) | 35 (76.1) | 27 (61.4) |
| Race, n (%) | ||||
| Black or African American | 30 (69.8) | 33 (71.7) | 36 (78.3) | 36 (81.8) |
| White | 11 (25.6) | 10 (21.7) | 10 (21.7) | 6 (13.6) |
| Other | 2 (4.7) | 3 (6.5) | 0 | 2 (4.5) |
| Body mass index, mean ± SD | 27.9 ± 5.2 | 28.2 ± 4.7 | 28.2 ± 5.0 | 31.3 ± 5.6 |
| PANSS score, mean ± SD | ||||
| Total | 99.0 ± 10.8 | 97.0 ± 8.8 | 96.3 ± 8.5 | 96.4 ± 7.7 |
| Positive symptom subscore | 26.7 ± 3.3 | 26.3 ± 3.4 | 26.2 ± 3.6 | 26.2 ± 3.1 |
| Negative symptom subscore | 23.3 ± 4.8 | 23.3 ± 4.9 | 21.9 ± 3.8 | 22.5 ± 4.2 |
| PANSS Marder factor score, mean ± SD | 22.6 ± 5.0 | 22.8 ± 5.4 | 21.9 ± 4.6 | 22.0 ± 4.5 |
| CGI-S score, mean ± SD | 5.0 ± 0.6 | 4.9 ± 0.7 | 5.0 ± 0.5 | 5.0 ± 0.5 |
CGI-S Clinical Global Improvement–Severity, PANSS Positive and Negative Syndrome Scale, SD standard deviation.